Status:
COMPLETED
WGS Analysis of COVID-19 Positive Patients
Lead Sponsor:
Vanda Pharmaceuticals
Conditions:
Coronavirus Infection
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
We aim to better understand the mode of action of COVID-19 in the context of its interaction with the host genome through whole-genome sequencing.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Ability and acceptance to provide written informed consent and fluent in English.
- Men or women between 18-100+ years, inclusive.
- Willing to comply with study procedures.
- SARS-CoV-2 positive test result as confirmed by a RT-PCR assay with a sputum or nasopharyngeal sample (either done prior to or at the screening visit).
Exclusion
Key Trial Info
Start Date :
August 3 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 9 2022
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT04353401
Start Date
August 3 2020
End Date
March 9 2022
Last Update
March 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanda Investigational Site
Cleveland, Ohio, United States, 44106